Post-Market Observational Study of Intra-Renal Drug Delivery (PROVIDE)
This is a prospective, observational, multi-center study with consecutive enrollment. Up to 1,000 patients will be enrolled. The objective of this post-marketing surveillance study is to collect clinical usage patterns of the Benephit Infusion Systems. As a result, FlowMedica will be able to:
- Better understand and quantify usage patterns including patient characteristics, adjunctive procedures, and infusion agents.
- Collect user-interface information and overall customer satisfaction.
- Monitor post-marketing device performance.
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Anticipated)
Enrollment
Contacts and Locations
Study Locations
-
-
California
-
La Jolla, California, United States, 92037
- Scripps Clinic
-
-
Kentucky
-
Owensboro, Kentucky, United States, 42303
- Owensboro Heart & Vascular
-
-
Louisiana
-
Lafayette, Louisiana, United States, 70506
- Cardiovascular Institute of the South
-
-
Oregon
-
Portland, Oregon, United States, 97225
- Providence Heart & Vascular
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Exposure to one or more components of the Benephit Infusion System
- Ability to give written informed consent
Exclusion Criteria:
- Inclusion in another clinical study that may affect usage of the Benephit system
Study Plan
How is the study designed?
Design Details
- Observational Models: Case-Only
- Time Perspectives: Prospective
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
1
All (consecutive) patients in whom one or more components of the Benephit Infusion System are planned to be used are eligible for enrollment in the study and should be offered informed consent.
|
Patient diagnosis, treatment, and follow-up are left to the discretion of the participating investigator.
There are no requisites as to how patients should be managed as this is intended to be an observational study.
No procedures other than usage of the Benephit Infusion System per its Instructions for Use are specifically required for participation in this study.
Other Names:
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: James A Tumlin, MD, Southeast Renal Associates
- Principal Investigator: David E Allie, MD, Cardiovascular Institute of the South
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start
Study Start
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
Other Study ID Numbers
- CL0015
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.